Thomas Marron

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Merck
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    EMD Serono
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Genentech
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Geneos
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    AbbVie
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    STORM
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    AstraZeneca
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    FATE
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Ono
    Date added:
    06/04/2024
    Date updated:
    06/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Avammune
    Date added:
    06/04/2024
    Date updated:
    06/04/2024

Pages

Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology